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Abstract
When spinal cord injury (SCI) occurs, numerous sources of reactive oxygen 
species and nitrogen species may be active within first minutes or hours and even 
reactivate few days later. Free radical formation and lipid peroxidation (LP) have 
been described as an important mechanism in the beginning and accelerated 
progress in the development of diverse pathologies, importantly in those related 
to central nervous system. The compromise of molecules and cellular structures 
due to the oxidative state of microenvironment in SCI may determinate survival or 
apoptosis of resident and infiltrating cells and polarization toward an inflammatory 
response, which lead to an extension of damaged tissue and loss of neuronal func-
tion, or a regulatory/regenerative response. The investigation of new antioxidant 
agents and their action at a molecular level begins to reveal mechanisms that, if cor-
rectly modulated, promise an improvement in recovery of functions with respect to 
conventional pharmacological therapies. In this chapter, we will review the general 
mechanisms of oxidative stress and lipid peroxidation, those antioxidant treatments 
in experimental development and clinical phase, as well as their achievements and 
limitations.
Keywords: antioxidant therapy, lipid peroxidation, free radicals, spinal cord injury, 
nitric oxide
1. Introduction
Among the different pharmacological strategies for treating spinal cord injury 
(SCI), it has been observed that the quick intervention after the injury results in 
a better outcome for the patients [1]. This can be explained by the biochemical 
processes occurring at a cellular level that develop immediately after the mechanical 
damage, which define the subsequent physiological chain of events determining the 
evolution of pathophysiology of the SCI and, therefore, the degree of functional 
loss or recovery. One of the most important processes participating in the bal-
ance between the prevalence of damage or protection of tissue structure and the 
function in the central nervous system (CNS) is the generation of diverse reactive 
molecules by oxidative stress that target mainly lipids. This process is known as lipid 
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peroxidation (LP), and its end products could modify proteins and DNA present 
in cellular structures, causing cell death and a lower probability of regeneration 
[2]. SCI is a highly disabling and irreversible condition that causes physiological 
complications (bowel, cardiac, urinary, respiratory) and it has a social-economic 
impact in patients. The research of new agents targeting degenerative processes 
such as oxidative stress and LP is important especially due to the lack of efficacy and 
safety of conventional therapies on patients with SCI [1]. Here, we review the efforts 
to discover new compounds aimed to offer an option in antioxidant treatments and 
the use of some in combination or in an innovative way, both in experimental and 
in clinical trials. We would like to mention that there is a wide range of antioxidant 
therapies in study, and we are only briefly mentioning some of them at this time.
2. Acute spinal cord injury mechanisms
The pathophysiology of the SCI has been divided in primary and secondary 
injury, the latter generally described in acute and chronic phases. The mechanisms 
involved in the secondary injury include biochemical degenerative processes that 
exacerbates damage, such as the loss of blood-spinal cord barrier (BSCB) integrity, 
ischemia/reperfusion, hypoxia, loss of ionic homeostasis, Ca2+ overload, glutama-
tergic excitotoxicity, immune cell invasion, inflammation, release of cytokines, 
free radical (FR) production, LP, and excessive production of nitric oxide (NO•). 
All these events occur in the acute SCI and may be clinically targeted due to their 
times of action, different from the unexpected primary injury [3] (Figure 1). It has 
also been demonstrated that these mechanisms are related in a way that exacerbates 
when the levels of oxidative stress and LP molecules are increased and that attenu-
ates its effects when the antioxidant treatment is immediately given after SCI [4].
2.1 Mechanism of oxidative stress and free radical’s generation
Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are mol-
ecules that participate in oxidative stress. They are endogenously produced under 
physiological conditions, and in low amounts, they are essential for biological 
and immune process [4]. Oxidative stress could be defined as a disturbance in the 
pro-/antioxidant equilibrium, for the presence of high levels of ROS and RNS that 
exceeds the endogenous antioxidative defense mechanisms, and they are associ-
ated with damage to a wide range of molecular species, such as lipids, proteins, and 
nucleic acids, contributing to the pathophysiology of SCI [3].
ROS are oxygen-derived compounds that include radicals (unstable molecules 
with a single unpaired electron), such as superoxide (O2
•−), hydroxyl (HO•) and 
peroxyl (RO2
•/HO2
•) radicals, and non-radicals such as hydrogen peroxide (H2O2). 
Within the first minutes and hours post-injury, different sources of O2
•− such as 
arachidonic acid cascade, mitochondrial leak, and enzymes systems [nicotin-
amide-adenine dinucleotide phosphate (NADPH) oxidase, myeloperoxidases, 
cyclooxygenase (COX), and xanthine oxidase], present in activated microglia 
and infiltrating cells (macrophages and neutrophils), may act providing O2
•− [5], 
derived from the reduction of oxygen molecules (O2) with a single electron (e
−). 
Although O2
•− itself is reactive, its direct oxidative reactivity toward biological 
substrates in aqueous environments is relatively weak, but it distinguishes itself as 
an active nucleophile and oxidizing agent that can react with hydrogen donors  
(e.g., ascorbate and tocopherol) [4–6]. On one hand, superoxide dis-
mutase (SOD) rapidly catalyzes the dismutation of O2
•− into H2O2 and O2 
(2O2
•− + 2H+ → H2O2 + O2), and at low pH, O2
•− can dismutate spontaneously.  
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In oxidative stress, this H2O2 can react with transition metal cations to form oxidiz-
ing species such as HO• and hydroxyl anion (HO−), and this occurs mainly in the 
presence of iron (Fe) and cooper (Cu) ions. The central nervous system (CNS) is 
rich in ferric iron (Fe3+), contained in transferrin in plasma, and ferritin intracel-
lularly. This iron can be released from its transporters at pH values of 6 or less, like 
the one reached in hypoxia and accumulation of lactic acid in SCI, and become 
Figure 1. 
Progression of the inflammatory response in spinal cord parenchyma. The condition produced by the 
mechanical injury induces the activation of the damage targeting mechanisms, initially propitiated by  
the resident microglia, which secretes pro-inflammaory cytokines. Astrocytes and endothelial cells allow the 
permeabilization of BSCB and express chemoattractants to facilitate the admission of immune cells from 
the periphery, increasing the response at site. Collateral injuries can occur, largely due to the low antioxidant 
capacity of neural tissue to counteract the ROS produced by inflammatory cells, spreading the damage to 
other uninvolved cells. The extent of the initial damage is proportional to the final capacity of the organism to 
recover its motor and sensory functions [155].
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catalytic; a second source for Fe comes from the hemoglobin released after mechan-
ical-induced hemorrhage. O2
•− acts donating an electron to Fe3+, and the ferrous iron 
(Fe2+) catalyzes the conversion of H2O2 to HO
• and HO−. Therefore, O2
•− and H2O2 
react in the presence of Fe3+/Fe2+ and promote the formation of HO• and HO− [2].
On the other hand, O2
•− can interact with NO•, a hydrophobic and mildly reactive 
radical generated enzymatically from L-arginine by nitric oxide synthase (NOS) 
isoforms, and give rise to one of the most important RNS, peroxynitrite ONOO− 
(NO• + O2
•− → ONOO−), a potent oxidizing and nitrating agent in vivo, either for 
direct oxidation reactions, in which it reacts with targets of low molecular weight 
and proteins (with thiols and metal centers), and carbon dioxide, or by derived 
radicals from homolytic cleavage, secondary to the reaction with carbon dioxide or 
protonation, included in RNS [2, 7]. Under biological conditions, ONOO− exists in 
equilibrium with its acidic form, the peroxynitrous acid (ONOOH), which decays 
rapidly by homolysis to give place to highly reactive nitrogen dioxide radical (NO2
•−) 
and HO• favored by the low pH in SCI [8]. Among the different direct reactions of 
ONOO−, one of the most relevant is this with CO2 (from bicarbonate buffer system), 
to form nitrosoperoxocarbonate (ONOOCO2), forming by cleavage strong oxidant 
agents, such as nitrogen dioxide (NO2
•−) and carbonate (CO3•−) radicals [7, 8].
2.2 Lipid peroxidation (LP)
Lipids are the most susceptible class of biomolecules to undergo oxidation; 
polyunsaturated fatty acids (PUFAs) are long-chain fatty acids with two or more 
double bonds in cis configuration, each separated by a methylene bridge (–CH2–) at 
their carbon backbone, and the hydrogen attached to the methylene bridge is very 
easy to remove. The LP is defined as an oxidative degradation and decomposition of 
lipids in an uncontrolled manner by nonenzymatic pathway and occurs when ROS 
react with PUFAs, leading to the modification of its physicochemical properties, 
disrupting the cellular membrane integrity. The enzymatic pathway produces lipid 
mediators such as prostanoids, leukotrienes, lipoxins, resolvins, and maresins by 
the action of COX or lipoxygenases (LOX), among others, causing dysregulation 
of blood flow, BSCB damage, inflammatory response, and programmed cell death 
pathway [9]. The CNS is particularly vulnerable to LP by various factors: it has high 
oxidative metabolic activity, PUFA content, and transition metal cations. In con-
trast, it has low antioxidant defenses and neuron-glia replication [8, 10].
The LP is a chain process that involves the participation of ROS, RNS, PUFAs, 
and oxidative systems, among others, where therapeutic intervention has been 
proposed with molecules that can both prevent FR formation and prevent those 
already formed from reacting with biomolecules. Because the peak of ROS produc-
tion occurs within the first 24 h after the injury, or during ischemia-reperfusion, 
the drugs that can be used for this “first FR production” are limited by their time 
of intervention. However, the phases in which LP develops may persist as long 
as there are oxidizable substrates, so knowing the reactions involved allows the 
design of strategies and drugs with a greater therapeutic window [11, 12]. The 
nonenzymatic peroxidation of PUFAs is the principal pathway of oxidative stress; 
HO• participates as one of the starts of LP due to its solubility and the lack of an 
enzymatic system to eliminate it. This and other radicals remove an H• radical inside 
a lipid (LH), which provides a lipid radical (L•) [11, 12] (Figure 2). The resonance 
stabilization of L• produces a conjugated diene that reacts with O2 to form a lipid 
peroxyl radical (LOO•) and generates a lipid hydroperoxide (LOOH) when it 
withdraws hydrogen from an adjacent PUFA, producing a second L• [2, 12]. The 
LOOH are regarded as the initial product of LP, but these compounds are unstable 
and can be discomposed with the participation of Fe3+ or Fe2+ again in LOO• or 
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alkoxyl (LO•) radicals, respectively. Both, the reduction of the LOO• to an LO• by 
Fe2+ (LOOH + Fe2+ → LO• + HO• + Fe3+) and its conversion back to LOO• (LOOH 
+ Fe3+ → LOO• + Fe2+) reactions, have acidic pH optimal conditions and are more 
likely to occur in SCI tissue environment [5]. The LO• can initiate chain reactions 
too, such as the LOO• reactions describe above. Thus, one HO• can generate a high 
number of LOOH through a series of chain reactions. Finally, termination of chain 
reactions occurs by the stabilization of the radicals reacting between themselves, 
Figure 2. 
The three steps of nonenzymatic lipid peroxidation of PUFAs. In the initiation step, a hydrogen atom at a 
bis allylic position is removed using either a radical or a redox active metal to generate a resonance-stabilized 
alkyl radical. The radical isomerizes to form the more stable conjugated diene, prior to reacting with molecular 
oxygen. In the propagation step, radicals are able to react with new substrates, forming lipid hydroperoxides 
(LOOH), which can react with iron creating new radicals. This step repeats until the termination step, 
where radicals are “quenched” by antioxidants or react with another radical. The decomposition of LOOH 
generates species such as MDA, HNE, etc. LH, lipid; L•, alkyl/lipid radical; LOO•, peroxyl radical; LOOH, 
lipid hydroperoxide; LO•, lipid alkoxyl radical; HNE: 4-hydroxy-2-nonenal; MDA: malondialdehyde; HHE: 
4-hydroxy-2-hexenal. Modified from Gaschler and Stockwell [12].
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forming a new bond and eliminating the radical, or by donating electrons (gener-
ally H•) to the radicals by compounds, without turning into radicals. In the case 
of LOOH provided in the previous LP reactions, these undergo fragmentation 
in which oxidized PUFAs give rise to short-chain secondary products, such as 
hydroxy-alkenals (neurotoxic aldehydes) relatively stable like malondialdehyde 
(MDA), 4-hydroxy-2-nonenal (HNE), 4-hydroxy-2-hexenal (HHE), and 2-pro-
penal (acrolein), that can diffuse within or even escape from the cell and attack 
targets far from the site of the original event [13] (Figure 2). In general, the LOOH 
can react in different ways that lead to a cleavage of the C-C bond and formation of 
hydroxy-alkenals by means of different mechanisms [13].
While the LP compromises the integrity of the cell membrane, the highly 
reactive secondary products can be covalently bound to proteins and DNA, com-
promising their structure and function. Regarding the HNE as the most studied 
product of LP, it must be mentioned that the HNE physiological concentration 
inside the cell ranges from 0.1 to 3 μM. Moreover, under oxidative stress conditions, 
HNE can accumulate at concentrations that range from 5 μM to 10 mM [14]. It has 
been demonstrated that HNE can play an important role as a signaling molecule, 
enhancing cellular antioxidant capacity and adaptive response at low concentra-
tions; can promote protein and DNA damage in organelles, leading to the induction 
of autophagy, senescence, or cell cycle arrest; and finally can induce apoptosis or 
necrosis programmed cell death at a high or very high level [13, 15, 16].
2.3 Proteins as target of oxidation
The oxidation of proteins for ROS can lead to the hydroxylation of aromatic 
groups and aliphatic amino acid (aa) side chains, nitration of aromatic aa residues, 
reversible nitrosylation of sulfhydryl groups, sulfoxidation of Met residues, conver-
sion of some aa residues to carbonyl derivatives, cleavage of the polypeptide chain, 
and formation of cross-linked protein aggregates. Furthermore, functional groups 
of proteins can react with products of LP and carbohydrate derivatives (glycation/
glycoxidation) to produce inactive derivatives [17], where the irreversible protein 
oxidation is described by four pathways: peptide bond rupture, carbonylation, 
formation of protein-protein bonds, and nitration [18]. The initial oxidation can 
form a carbon-centered radical, which can react with O2 to form a ROO
•, to cleave 
protein backbone by either α-amidation or diamide pathways.
The cleavage of side chains (glutamyl, aspartyl, and probably prolyl side chains) 
may occur directly or by metal-catalyzed oxidation (proline [Pro], arginine [Arg], 
lysine [Lys], and threonine [Thr] residues), yielding carbonyl derivatives [17, 18]. 
One of the most important of irreversible oxidation processes is by protein carbon-
ylation. It involves the previous protein and aa carbonyl derivatives ,CO3
•− oxidation 
(reacting preferentially on tryptophan [Trp], Thr, cysteine [Cys], methionine 
[Met], and histidine [His] residues), ketones and aldehyde reactions over Cys, Lys, 
His, and by glycation/glycoxidation of Lys amino groups, etc. [2, 8, 17, 18].
The modification of the protein structure after oxidation can also give rise to 
intra- or inter-protein cross-linked derivatives by several different mechanisms. For 
example, the protein-protein bond may be due to the interaction of two carbon-
centered radicals or two aromatic aa residues radicals, formed by direct attack of 
ROS [17]. Final products of LP, such as HNE and MDA, can cause cross-linked 
proteins, as reactions of both MDA aldehyde groups with two different residues 
in the same protein or two different proteins [17]. Another protein-protein bond 
is disulfide bridge (RSSR) that results from the oxidation of thiols (RSH) form-
ing sulfenic acid (RSOH) as the last intermediate and reacting with another thiol, 
forming RSSR. This can be promoted in the presence of OONO− or driven by ROS 
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and RNS, with the possibility of chain reactions [8]. Regarding this, some enzymes 
containing Cys, in its catalytic site, can act as scavengers, by direct interaction or 
consuming glutathione (GSH), due to the reversible modification of the RSSR 
bond [8]. HNE possess three functional groups in its structure (Figure 2), mak-
ing this electrophilic molecule highly reactive toward nucleophilic groups such as 
thiol (–SH) and amino (–NH2). Thus, aa such as Cys, Lys, His, and Arg are HNE 
targets, whose modification inhibits the functions of a variety of enzymatic and 
structural cellular proteins [19]. MDA with enhanced reactivity in low pH and 
existing as β-hydroxyacrolein is strongly reactive to nucleophiles such as Lys, His, 
or Arg residues [20]. Protein modifications by RNS act over aromatic, Cys, and Met 
residues; OONO− reacts directly with thiol groups present in a variety of proteins 
such as GSH, albumin, and metalloproteins (heme, myeloperoxidase, cytochrome 
P450, SOD isoforms, etc.) forming nitrite (NO2
−), nitrate (NO3
−), or NO2
•− [8]. 
Finally, irreversible protein tyrosine nitration by NO2
•−, with substitution of a 
hydrogen in the position 3 of the phenolic ring, produces 3-nitrotyrosine (NT-3) 
as a specific footprint of induced cellular damage by OONO− [2, 8]. From all these 
modifications, diverse molecules can be identified both in cerebrospinal fluid and 
blood, both in humans and in animals, and they have been proposed as biomarkers 
to diagnose the severity of SCI. Some of those biomarkers derived from proteins are 
neurofilament proteins, glial fibrillary acidic protein (GFAP), tau, neuron-specific 
enolase, and S100 calcium-binding protein β (S100β), being part of the components 
of neurons, oligodendrocytes, and reactive astrocytes. A more detailed list can be 
found in the works of Lubieniecka et al. and the Hulme et al. review [21, 22].
2.4 DNA damage
The ROS/RNS produced in oxidative stress and LP can damage the nucleic acids 
of DNA; cause DNA-protein cross-links, strand breaks, and modification of purine 
and pyridine bases; and lead to DNA mutations. More than 20 DNA adducts have 
been identified, such as 8-hydroxy-2′-guanosine (8-OHdG), increased in patients 
in whom the antioxidant systems are suspected to be deficient [23]. MDA is an 
important contributor to DNA damage and mutations that can react with several 
nucleosides (deoxyguanosine and cytidine) to form adducts, and the major result-
ing product is a pyrimido-purinone called M1dG [24]. HNE can also react with 
deoxyguanosine to form two pairs of diastereomer adducts (4-HNE-dG 1,2 and 3,4) 
or etheno-DNA adducts in the presence of peroxides that could further induce DNA 
cross-link or DNA-protein conjugates [25, 26]. Other markers of oxidative damage 
in DNA, among other biomolecules, were reviewed in [23].
2.5 Enzymatic and nonenzymatic antioxidant systems
The cellular antioxidant systems are composed by antioxidant enzymes and 
nonenzymatic molecules able to donate electrons to different radical chemi-
cal structures. In the CNS, they are present in lower concentrations than the 
oxidizable substrate and are responsible of maintaining the pro-/antioxidant 
equilibrium, relieving oxidative stress, and reducing or interrupting uncontrolled 
LP, DNA mutations, protein oxidation/degradation, as well as other cell damage 
features. The essential endogenous components of the enzymatic antioxidant 
defense are SOD, catalase (CAT), glutathione peroxidases (GPx), glutathione 
reductases (GR), and glutathione S-transferases (GST), while the nonenzymatic 
antioxidants include GSH, proteins (ferritin, transferrin, ceruloplasmin, metallo-
thionein, thioredoxin (Trx), albumin), vitamins C and E (tocopherol), trace 
elements, and low molecular weight scavengers, such as uric acid, coenzyme Q , 
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and lipoic acid [4, 6, 23], which act by depleting molecular O2 or decreasing its 
local concentration; removing pro-oxidative metal ions; trapping aggressive ROS, 
such as O2
•− or H2O2; scavenging chain-initiating radicals like HO
•, RO2
•/HO2
•, 
or LO•; or breaking the chain of a radical sequence [4]. There are also important 
exogenous nonenzymatic antioxidants (vitamins A, C, E, flavonoids, carotenoids, 
phenolics, acetylcysteine, exogenous selenium, zinc), acquired through diet, 
which are being studied. A table of these enzymatic and nonenzymatic anti-
oxidants important in the CNS was reviewed in [23]. Preventing the formation 
of ROS, or at least its accumulation, and blocking or capturing those radicals 
already formed is the first defense against oxidative stress. The O2
•− generated by 
various sources can be converted to H2O2 by SODs [4]. The O2
•− intracellularly 
produced in the mitochondria can be converted into H2O2 by MnSOD (SOD3) 
[18]. Once generated, H2O2 (but not other peroxides) is decomposed to water 
and oxygen O2 (2H2O2 + 2GHS → H2O + O2) by the action of CAT, a ferriheme-
containing enzyme. However, small amounts of ROS escape from the antioxidant 
defense and can be converted to HO•, which may be scavenged by low molecular 
mass nonenzymatic antioxidants, such as ascorbate, tocopherol, GSH, etc. 
[27]. H2O2 is also reduced by the action of different peroxidases, such as GPx 
(H2O2 + 2GHS → H2O + GSSG), which, additionally, can reduce lipid hydroperox-
ides (LOOH + 2GSH → LOH + GSSG) [11, 12]. Other enzymes that catalyze this 
reaction include peroxiredoxin and thioredoxin reductase [4]. Some enzymes that 
participate in the detoxification of LP products by oxidation, reduction, and glu-
tathione conjugation, the latter being a mechanism also used to reverse the effects 
of RNS, are aldehyde dehydrogenases (ALDH), alcohol dehydrogenase (ADH), 
aldo-keto reductase (AKR), and the aforementioned GST, GPx, and GR [28].
In SCI, the primary injury causes disruption of blood flow and vascular insult, 
such as ischemia-reperfusion, which conducts to the loss of metabolic function of 
cells in gray matter with decrease of ATP, causing depolarization of membranes 
due to the inhibition of Na+/K+ and Ca2+ ATPases function. Ca2+ overload and 
glutamate excitotoxicity compromise the function and integrity of mitochondria 
through the activation of proteases and inactivation of important enzymes. Due 
to the low ratio of antioxidant systems’ oxidizable substrate in acute SCI, the 
mitochondrial antioxidant reserves decrease and are incapable of restoring the 
redox equilibrium, giving place to an increase of mitochondrial concentration 
of O2
•− and an increase and leak of free radicals formed downstream including 
ONOO−, initiating LP. The damage produced by this excess of radicals or end 
products of LP over proteins and membranes of the mitochondria and endoplas-
mic reticulum potentiates the processes of secondary injury mentioned here to the 
local and adjacent cells to SCI [4].
3. Antioxidant therapy strategies
The early therapeutic intervention for SCI is crucial to improve the chances of 
maximum possible recovery. This was observed in clinical trials where the cur-
rent treatment of choice, methylprednisolone sodium succinate (MP or MPSS), 
was effective only when administered within the first 8 h after injury, at high 
doses (5.4 mg/kg/h). In 48-h regimens, however, it increases the incidence of 
complications from infections (severe sepsis and pneumonia), while the 24-h safe 
regimen is not effective in the long term, at least after 3 h [1]. Being an ineffec-
tive treatment, there are no alternative therapeutic treatments that offer safety 
and certainty regarding the recovery of the motor function. The research of new 
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pharmacological agents for the treatment of SCI focuses on the processes of sec-
ondary injury, being antioxidant therapies the most important. The main goals of 
drug therapies for SCI can be classified in neuroprotection and neuroregeneration; 
antioxidant therapies are cataloged within the first. Here we present some of the 
agents that are in experimental phase and others when mentioned, in clinical trials, 
either because their efficacy has been demonstrated in animal models or because of 
their use already approved in other pathologies. Regarding the diverse SCI models, 
they have been used to simulate SCI with high relevance and validity to preclini-
cal evaluation due to the replication of human traumatic injuries. The rational 
use of animals is strongly controlled, and the possibility of pain and distress must 
be considered and minimized by veterinary staff through the appropriate use of 
analgesics and animal care.
3.1 Melatonin
Melatonin (N-acetyl-5-methoxytryptamine) is a pleiotropic compound that 
works mainly in the regulation of circadian rhythms and sleep. When reacting with 
ROS, such as HO−, H2O
•, and LOO•, it is converted to cyclic 3-hydroxymelatonin. 
It stimulates the expression and activity of SOD, GPx, CAT, and GR and inhibits 
or decreases the expression of pro-oxidative NOs, different signaling pathways, 
transcription factors, and pro-inflammatory cytokines [29–31]. Decreased melato-
nin production has been linked to various CNS disorders, and the neuroprotective 
activity was detected in rat models of traumatic brain injury ischemic stroke and 
SCI [29, 30]. To cite only some SCI examples, in a study in Sprague-Dawley rats of 
250 g with moderate lesion, 10 mg/kg of melatonin was applied subcutaneously 
twice a day for 4 weeks, and an increase in motor recovery and decrease in inducible 
nitric oxide synthase (iNOS) expression were observed. Intravenously, it decreased 
the synthesis of MDA and increased the synthesis of GSH and angiopoietin 1, and 
in mice with severe lesion, it decreased the expression of interleukin 1 beta (IL-1β) 
and NG-2 (neuron/glial antigen 2) [30, 32, 33]. In a model with lesion with vascular 
clips, the administration of 30 mg/kg alleviated post-traumatic injury associated 
with SCI by binding the PPARα-receptor; the administration of 50 mg/kg in moder-
ate lesion decreased the BSCB permeability modulating the expression of brain-
derived neurotrophic factor (BDNF), growth-associated protein 43 (GAP-43), and 
caspase-3 [33–35]. In combination therapy with dexamethasone (10–0.025 mg/kg), 
it showed significant anti-inflammatory effects, attenuating the synthesis of tumor 
necrosis factor alpha (TNF-α) and iNOS and the nitration of tyrosine residues, 
increasing tissue recovery and motor capacity in an experimental SCI model of 
mouse [36], while the combination with methylprednisolone favored neurologi-
cal recovery and decreased LP; its administration with zinc activated the internal 
antioxidant system and also decreased the LP [37–39].
3.2 Minocycline
Minocycline hydrochloride is an available semisynthetic tetracycline antibiotic 
with potent anti-inflammatory (regulation of phospholipase A2 and MAPK/PIK3 
pathways) and neuroprotective (protecting against glutamate-induced inflam-
mation) activities; it also inhibits matrix metalloproteinases and mitochondrial 
Ca2+ influx. Minocycline has antioxidant and antiapoptotic properties, probably 
acting at high doses as a direct radical scavenger, like vitamin E, due to its phenolic 
ring structure [40]. In rats with SCI, minocycline given at oral doses of 3, 30, and 
90 mg/kg 1 and 24 h after the lesion reduced MDA concentration and increased 
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GPx and SOD activity in a dose-dependent manner [41]. Minocycline decreased 
pro-inflammatory cytokines and the chemokines release from microglia and their 
activation, including their levels of enzymes that regulate LP and NO production 
[42]. A recovery difference between treatment and placebo, approaching to statisti-
cal significance in patients with cervical injury, was shown in a phase II clinical 
trial. The trail determined safety and dose optimization, within 12 h of SCI and for 
7 days, with steady-state concentrations of 12.7 µg/mL in serum and 2.3 µg/mL in in 
cerebrospinal fluid (ClinicalTrials.gov number NCT00559494) [43].
3.3 Estrogen
Treatment with gonadal steroid hormones (estradiol, testosterone, estrogen) 
has resulted in motor recovery with a reduction of the lesion volume in animal 
models. Through its receptors (ERα and ERβ), estrogen exerts neuroprotection at 
physiological concentrations, and it exerts better neuroprotection as an anti-
oxidant at high concentrations. Estrogen modulates gene expression; promotes 
angiogenesis; inhibits inflammation, blocking microglia from releasing inflam-
matory molecules such as TNF-α, ROS, prostaglandin E2, etc.; regulates the 
expression of antioxidant enzymes; and induces mitochondrial GSH production 
[44]. Different low doses and times of administration (between 10 and 100 μg/
kg/day/7 days to 4 mg/kg/15 min and 24 h, i.v.) appear to be effective, suggesting 
that pre-treatment or immediate posttreatment at either physiological or supra-
physiological dose could minimize secondary injury in SCI and promote func-
tional recovery, reflected in both acute and chronic stages [44, 45]. Additionally, 
the development of selective agonists of ER with higher affinity for ERα, ERβ, 
or both, such as tamoxifen, looks promising in SCI treatment, when applied in 
subdermal implants 7 days before, immediately, or 24 h post-injury; with an 
immediate release of 0.71 mg/day for 21 days, it provided motor recovery and 
preservation of white matter, dorsal and ventral horn neurons, with a decrease of 
O2
•− production [46].
3.4 Omega-3 fatty acids
The omega-3 fatty acids: α-linolenic acid, eicosapentaenoic acid (EPA, with five 
unsaturated bonds), and docosahexaenoic acid (DHA, with six unsaturated bonds) 
are part of the triacylglycerols that are consumed in the diet. DHA is a primary 
structural component of human brain, cerebral cortex, and retina. The lack of DHA 
may affect the fluidity and integrity of the membrane in synaptosomes; addition-
ally, it affects the architecture of proteins that act as receptors and channels. Several 
studies have studied the effects of DHA in SCI, with treatments that include intra-
venous bolus, nutritional supplementation, and the use of transgenic [47]. In SCI in 
rats, a single application of DHA (250 nmol/kg, i.v., 30 min after injury) showed an 
improvement in motor recovery, smaller lesion size, greater survival of neurons and 
oligodendrocytes, and lower oxidation of DNA/RNA in comparison to rats without 
treatment [48]. More details of the application of DHA in SCI are mentioned in the 
chapter on Samaddar [47], as well as interesting effects on molecules involved in the 
repair and conservation of axonal integrity.
3.5 Endogenous antioxidants (vitamins C, D, and E and ubiquinol)
Several molecules that already act as endogenous antioxidants have been studied 
as candidates for application in antioxidant therapies for SCI. Vitamin C, or ascor-
bic acid, is a small water-soluble molecule that has a double bond and participates in 
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various metabolic processes as a reducing agent. It is considered nontoxic because it 
does not accumulate and its concentration declines during SCI. In rats, it decreases 
tissue inflammation and necrosis and only at high doses (200 mg/kg i.p. 1-h post-
injury, daily, until they were sacrificed, 4th week) showed improvements in motor 
evaluations [49]. Vitamin D (1,25-dihydroxyvitamin D3, VDH, active form) is a 
molecule with cholesterol skeleton and acts similarly to hormones and steroids on 
several systems. Its receptor (VDR) is widely distributed in the CNS, and it appar-
ently acts on the same targets as progesterone through similar pathways. Its use in 
CNS damage models in vivo and in vitro has shown promising results on several 
aspects. The prolongation or exacerbation of inflammation also gives way to greater 
damage by oxidative stress; therefore, the effect of VDH in vivo on the inhibition 
of iNOS and increase of IL-4 and TGF-β and in vitro modulating the production 
of molecules involved in oxidative stress, neurotoxic damage, and axonal growth 
on various cells are of interest for being use in SCI [50]. Tocopherols are a group of 
four fat-soluble phenolic compounds designated α, β, γ, and δ, which are found in 
vegetable oils, being alpha (α-T, considered the classic vitamin E) the one with the 
highest proportion in blood and tissues. All tocopherols are strong chain breaking 
antioxidants by effectively scavenging ROS and RNS. α-T significantly reduces the 
activity of iNOS and COX-2 [51]; in addition, the effect of extracts or synthetic 
derivatives has been evaluated, decreasing cell death due to excitotoxicity and oxi-
dative stress in astrocytes [52] and accelerating remyelination of focal demyelinated 
lesions chemically induced [53]. In rats with SCI, the use of α-T (600 mg/kg i.m., 
twice weekly, for 6 weeks) decreased the damage caused by ischemia-reperfusion, 
improving the levels of motor and sensory recovery and the level of oxidative stress 
[54]. Ubiquinol (reduced form) or coenzyme Q10 is among the antioxidants that 
decrease their concentration after SCI. It is a fat-soluble cofactor present in the 
inner mitochondrial membrane acting as an antioxidant in the respiratory chain. 
Previously, the effect on ischemia-reperfusion damage in the CNS has been proven, 
preventing LP and reducing the size of the lesions [55].
3.6 Immunotherapy
The use of antibodies in the treatment of SCI is diverse and is directed to 
the functions of immune cells involved in inflammation and the pathological 
process. The initial invasion of leukocytes depends on the interaction of CD11d/
CD18 (cluster of differentiation; CD) integrin with vascular cell adhesion mol-
ecule-1 (VCAM-1). In the case of the use of  anti-CD11d monoclonal antibody 
administered in rats to determinate the therapeutic window with 1 mg/kg doses 
i.v. on groups at different times of application (2, 6, 12, 24, or 48 h post-lesion), 
it was shown that the treatment beginning even up to 6 h after the lesion resulted 
in an attenuation of infiltrating leukocytes (neutrophils and macrophages, 
sources of ROS and RNS), lowered the expression of COX-2 and iNOS, and 
lowered the amounts of HNE, NT-3, and dinitrophenyl (DNP) (used for the 
detection of protein carbonylation) therefore acting as an indirect antioxidant. 
This treatment also showed improvement in motor recovery vs. a control anti-
body [56]. Another important integrin is the dimer α4β1 also known as very late 
antigen 4 (VLA-4), and treatments with anti-α4 blocking monoclonal antibodies 
(2.5 mg/kg/2 and 24 h/i.v.) or small molecule blocker BIO5192 (10 mg/kg/2 h/
continuous i.v. infusion for assessment of oxidative damage) showed a decreased 
influx of neutrophils/macrophages, reduced oxidant activity (COX-2, NO or 
iNOS, MDA), preserved white and gray matter, improved motor function in 
different evaluations, and decreased mechanical allodynia after SCI, when 
compared with the controls [57, 58].
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3.7 Antioxidant peptides
3.7.1 A91 peptide
Modified neural peptides are peptide analogs of the myelin basic protein (MBP) 
epitopes that possess one or more aa substitutions and that have a partial agonist or 
antagonist action when in contact with the T lymphocyte (TL) receptor [59, 60].
Schwartz and Hauben tested the administration of non-encephalitogenic peptides 
of different aa sequences associated with MBP, which are named according to the posi-
tion of the aa substitution that is performed: A96, G91, and A91, among others. A91 
showed the best results after a traumatic injury, both in the optic nerve and in spinal 
cord, without showing clinical signs of autoimmune disease, hypersensitivity, immu-
nosuppression, and controlling the destructive action of autoreactive TL [61, 62].
A91 is a peptide belonging to the aa 87–99 sequence of MBP with the sub-
stitution of an aa at position 91 of a lysine (VHFFKNIVTPRTP) by an alanine 
(VHFFANIVTPRTP), functioning as a partial agonist peptide and promoting 
a change of the profile of cytokines produced by TL reactive against the 87–99 
sequence of the MBP of a Th1 phenotype (interferon gamma [IFN-γ], TNF, IL-2) to 
a Th2 (IL-4, IL-10) and decreasing the action and synthesis of the FR, among other 
effects [63]. A91 allows activating the microglia with a phenotype producing neu-
rotrophic factors, which together with the release of factors produced by other cells 
such as monocytes (MN) and TL reduce secondary neuronal degeneration [64–66].
The beneficial effect of subcutaneous immunization at the base of the tail has 
been demonstrated with A91 at a single dose (150–200 μg/kg) after SCI due to mod-
erate contusion. This immunization, among various factors and effects, promotes 
neuroprotection and motor recovery by decreasing the expression of iNOS and pro-
duction of NO•, LP, caspase 3, and pro-inflammatory cytokines and increasing the 
release of neurotrophic factors such as BDNF and NT-3. The effect of the immuniza-
tion is preserved in the chronic stage of the lesion and as a prophylactic treatment or 
up to 72 h after the SCI; however, it diminishes when applied to lesions due to severe 
contusion or complete medullar cut and is eliminated with a double immunization. 
It has also been determined that the severity of the lesion determines the profile of 
genetic expression in the lesion after immunization and that immunization plus 
the removal of the fibroglial scar and/or the implant of a scaffold as support for 
mesenchymal stem cells favors a permissive microenvironment for motor recovery 
and improves the electrophysiological activity in the chronic stage after a complete 
section of the spinal cord [67–73]. The protective response of A91 is between 4 and 6 
days, indicating that it acts on subsequent mechanisms to the acute stage. During this 
time, the oxidative processes are not completely modulated. Regarding this, it has 
been shown that the therapeutic combination of A91 peptide with peptides acting 
at shorter times, such as glutathione monoethyl ester (GSH-MEE) or the monocyte 
locomotion inhibitory factor (MLIF), reduces FR and LP and induces better motor 
recovery, neural survival, presence of myelinated axons, and tissue protection. In the 
same way, it was demonstrated that the combination of A91 with GSH-MEE retains 
the effect if applied until 72 hrs after the lesion [68, 74, 75].
3.7.2 Monocyte locomotion inhibitory factor (MLIF) peptide
MLIF is a pentapeptide (Met-Gln-Cys-Asn-Ser). In vitro studies showed that 
MLIF decreases MN locomotion, the production of ROS (H2O2, O2
•-, HO•), NO•, and 
cGMP, and it induces an increase of microtubules associated to the centriole and the 
concentration of cAMP [76–78]. The pharmacophore group of the MLIF is integrated 
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by the Cys-Asn-Ser tripeptide, which retains the same biological activities of the 
factor [79, 80].
The MLIF favors the Th2 response; modulates the synthesis of pro-/anti-inflam-
matory cytokines and the expression of genes involved in inflammation, prolifera-
tion, angiogenesis, synthesis/degradation of extracellular matrix, angiogenesis, and 
axonal guidance, among others; and acts mainly through the signaling pathways: 
NF-kB, MAPKinases, and eEF1A1/endothelial nitric oxide synthase [81–84].
In vivo, the factor retards the arrival of MN in Rebuck windows and inhibits 
cutaneous delayed hypersensitivity to dinitrochlorobenzene, while in guinea pigs, it 
lobs down the expression of VLA-4 and VCAM-1 adhesion molecules in postcapil-
lary vascular endothelium and decreases the formation of pericardial adhesions in 
rats when applied directly to the site of injury after surgery [85].
Studies in cerebral ischemia showed that the penetrating, antioxidant, anti-
inflammatory, and neuroprotective capacity of the pharmacophore group is favored 
in analogs when the N-terminal end is modified by adding one of the following 
aa: Asp, His, Try, or Arg. In the same way, cardioprotective effects have been seen 
in myocardial ischemia [86, 87]. On the other hand, pharmacokinetic studies are 
underway to determine the concentration of MLIF in plasma [88].
In base studies of our group, rats were subjected to a moderate SCI, and a dose 
of 200 μg of MLIF was applied directly to the site of the lesion. The animals treated 
with the factor presented a greater motor recovery than the non-treated, and a 
decrease in the LP, the concentration of NO•, and the expression of the iNOS. An 
increase in the expression of the IL-10 and TGF-β (Transforming Growth Factor 
beta) genes was observed at 3 h and 7 days post-injury, favoring the survival of the 
ventral horn neurons [75]. Subsequent studies showed that four doses of the MLIF 
at the same concentration immediately initiating direct administration at the site 
of injury and subsequently one dose every 24 h for 3 days by i.p. administration 
are sufficient to improve motor recovery in rats subjected to SCI. In the same way, 
therapeutic combinations of MLIF, at different times and doses, have favored the 
effect of the MLIF in the experimental model of SCI modulating the synthesis of 
the FR and ROS.
3.7.3 Glutathione (GSH) peptide
GSH (Figure 3) is a tripeptide (L-γ-glutamyl-L-cysteinyl-glycine), nonprotein 
thiol. It is synthesized in the cellular cytoplasm by the consecutive action of two 
enzymes. The first, γ-glutamylcysteinyl ligase, is regulated by the nuclear factor 
(erythroid-derived 2)-like 2 (NFE2L2 or Nrf2), which is sensitive to oxidative 
stress. This enzyme uses glutamic acid (Glu) and Cys aa, glutamic acid (Glu) and 
Cys aa, as a substrate to form the γ-glutamylcysteine dipeptide (γ-GluCys), which 
Figure 3. 
Condensed structural chemical formula of glutathione (IUPAC name: (2S)-2-amino-4-{[(1R)-1-
[(carboxymethyl) carbomoyl]-2-sulfanylethyl] carbomyl1} butanoic acid). Modified from Gaucher et al. [89].
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is combined with glycine (Gly) in a reaction catalyzed by the second enzyme 
(glutathione synthase) to form GSH, whose concentration is regulated by the 
nhibition of γ-GluCys ligase, the cellular content of L-cysteine, and the final 
concentration of GSH. Thus, the intracellular and extracellular concentrations of 
GSH are determined by the balance among its synthesis, catabolism, and trans-
port between cytosol and the different organelles [89].
GSH, by itself, is not transported effectively into the cells, and under normal 
physiological conditions, it is in a reduced form. During its oxidation (where the thiol 
group of Cys is responsible for the redox reactions) by ROS and RNS, it involves two 
types of reactions, a nonenzymatic reaction with the NO•, HO−, and O2
•− radicals and 
an enzymatic one providing an electron for the reduction of peroxides in the reac-
tion, catalyzed by GPx to form the oxidized glutathione GSSG (two GSH molecules 
bound by the disulfide bridge), which is regenerated by Gr, an enzyme that transfers 
electrons from NADPH to GSSG by reducing it [90, 91]. Thus, the redox state of GSH 
activates the activator protein 1 (AP-1) responsible for the expression of cytokine 
genes, TGF-β, and collagenase and AP-2 responsible for the activation of c-Jun-N-ter-
minal kinases (JNK), stress-activated protein kinases (SAPK), protein kinase c (PK-
C), and tyrosine kinase, while the decrease in the GSH level stimulates the activation 
of NF-κB, protein kinase B, c-Jun N-terminal Kinase, and mitogen-activated protein 
kinase with the subsequent increase in synthesis of pro-inflammatory cytokines and 
caspases. In suitable concentrations, GSH increases the activation, proliferation, and 
cellular differentiation and regulates the Ca2+ homeostasis [91], granting a fundamen-
tal role in cellular homeostasis and pathologies related to patient’s age and oxidative 
stress states, such as neurodegenerative, neuroinflammatory, cardiovascular diseases, 
and cerebral ischemia, among others [92, 93]. To increase the intracellular GSH con-
centration levels, GSH precursors have been used, without modifying the Cys that is 
critical for the functioning of the peptide. GSH precursor molecules such as N-acetyl 
cysteine (NAC) stimulate the biosynthesis of GSH that acts directly on ROS, RNS [89, 
93, 94], and glutathione esters, mainly mono- and dimethyl esters such as glutathione 
monoethyl ester [γ- Glu-Cys-Gly-OEt (GSH-MEE)], where the carboxyl group of Gly 
is esterified and, due to its high hydrophobicity, increases its permeability to the cell 
membrane and facilitates its transport in brain-spinal fluid [95–97]. Once GSH-MEE 
is located in the cellular cytoplasm, it is hydrolyzed by the intracellular esterases to 
release and cause the intracellular increase in the GSH concentration and react with 
the FR without enzymatic intervention or it reduces the peroxides by means of GPx 
through its oxidation to GSSG [89, 91, 98, 99].
GSH-MEE has been used effectively to protect cells from oxidizing agents and 
various toxic compounds in various cell lines and animal models with neurodegen-
erative and inflammatory processes [92, 99, 100]. Studies of our group and collabo-
rators have shown that the i.p. administration of 12 mg/kg of GSH-MEE divided 
into four doses in the first 24 h post-lesion in rats subjected to a moderate SCI 
contributes to the reduction of oxidative stress, significantly improves motor func-
tion and survival of red core neurons, and stabilizes spinal cord blood flow [100], 
while a therapeutic combination of GSH-MEE (at the same dose and under the same 
scheme) with intradermal application (i.d.) of the A91 peptide at the base of the tail 
at a dose of 600 μg/kg immediately after the injury promotes a better neurological 
recovery and morphological preservation. This combination is able to maintain its 
neuroprotective action even if it starts 72 h after the injury [68, 74]. In the same 
way, our group has demonstrated that the therapeutic combination of GSH-MEE 
and MLIF promotes greater motor recovery and maintains several morphological 
aspects on the site of lesion in rats subjected to moderate SCI.
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3.8 Natural extracts as antioxidants
A variety of ingredients and active ingredients derived from herbal extracts, 
known for their antioxidant and anti-inflammatory activity, have also called 
the attention to complement SCI treatments. Among all these, ingredients such 
as curcumin, resveratrol, epigallocatechin gallate, ligustrazine, quercitrin, and 
puerarin and herbs such as Dashen, Ginkgo biloba, Ginseng, Notoginseng, and 
Astragali Radix are outlined as candidates for various experimental studies. In the 
review by Zhang et al. [101], the molecular structures, application, and dose are 
listed, as well as the results found at a molecular level on SCI. In particular, the 
compound curcumin is a polyphenol substance isolated from the yellow extract 
from rhizome of Curcuma longa, and it has been widely used for medicinal purposes 
due to its potent effect in inhibiting acute and chronic inflammation. Regarding its 
antioxidant action, its application in SCI (300 mg/kg in DMSO, single dose i.p. after 
injury) has shown a decrease in MDA and an increase in SOD at 24 h [102], and at a 
lower dose, it has also increased the concentration and induction of GSH, GPx, and 
Nrf2 and decreased the expression of NF-κB, TNF-α, and IL-1β [101].
3.9 Spin trappings
A highly studied antioxidant strategy consists of scavengers of FR that include, 
among others, thiols (lipoic acid), GSH precursors, NAC, polyphenolic compounds, 
hydroxyl stilbenes, nitrones, and spin trappings (noncyclic and cyclic nitrones); we 
will only review the latter. Most spin trappings have a nitronate or nitroxide nucleus 
and are chemical agents that react with FR, forming stable products (adducts), and 
were originally developed as a tool to detect and stabilize the FR in chemistry and 
later in biological oxidation processes [103–105]. The first spin trappings had short 
half-lives and generated toxic HO•. By designing the spin trappings with the inclu-
sion of heterocyclic rings (pyrrolines or phenol, generating Imidazolyl-nitrones, 
Furil-nitrones, Arylnitrons, and others) toxicity was reduced, improving its neu-
roprotective, anti-inflammatory, functionality, stability, bioavailability, and trap-
ping different types of FR centered on O2, carbon, and sulfur derivatives. In turn, 
this increases their solubility in high concentrations in a large number of solvents 
(~0.1M), producing a positive effect when administered in a varied-dose scheme 
before or after a traumatic event [103, 106]. A basic example of the nitrones is phenyl 
N-tert-butylnitrone (PBN), an arylnitrone with general formula X-CN = NO-Y, 
which acts by reacting with O2
•− and/or HO− to produce adducts. Once the adduct 
is formed, the radical is inactivated and unable to damage the cell tissue [104, 107]. 
The general reaction is that of the formation of adduct, schematized in Figure 4. In 
general, it is indicated that PBN is not toxic and the suitable concentration to form 
adducts is 10–15 mg/100 g of weight, while the estimated lethal dose is 10 times 
higher (100–150 mg/100 g of weight) [108]. The first neuroprotective evidence 
was in neurodegenerative models administered at low doses after injury and in the 
Figure 4. 
Basic reaction of a nitrone with FR to produce a stable spin product (adduct). Modified from Refs. [105, 106].
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prevention of stroke-induced mortality in models of ischemia in gerbils [103, 104, 
109–113]. The pharmacological effects of PBN in animal models are extensive, 
protecting against death after endotoxic shock, bacterial meningitis, teratogenicity 
induced by thalidomide, diabetogenesis, hepatocarcinogenesis, etc. Many stud-
ies have reported a neuroprotective effect in SCI and the brain (the most studied) 
decreasing the expression of genes associated with apoptosis, inflammation, and 
iNOS by decreasing the activation of MAP p-38 NF-κB nitrogen kinase and syn-
thesis of NO• [114]. In a process of ischemia or perfusion, PBN reduces the size of 
the infarct by increasing ischemic reperfusion and decreasing neurodegeneration, 
excitotoxicity, and the activation of microglia; it also induces neurite growth through 
indirect activation of the Ras-ERK pathway, increasing animal survival [106, 
115–117]. The neuroprotective effect of PBN is attributed to its ability to quickly 
and easily penetrate the membranes and the blood-brain barrier with a half-life of 
3 h in plasma; decrease the levels of oxidized proteins, 8-isoprostane, HNE, IL-1β, 
TNF-α, IFN-γ, c-fos, IL-3, IL-4, IL-5, and H2O2; and favor an increase of GHS and 
IL-10, among others [106, 117–119]. In a model of cortical contusion in rats, it was 
demonstrated that pre-treatment with PBN with a single intravenous dose of 30 mg/
kg 30 min before the injury reduces the cognitive deficit and its volume; it has shown 
to have a wide therapeutic window in focal ischemia rodent models, reducing the 
infarct volume when administered up to 12 h after the beginning of the stroke and 
reducing the loss of tissue when administered by fluid percussion 30 min. After 
injury in rats [120]. Currently, the nitrones derived from PBN [102] are being widely 
studied as neuroprotective in different CNS pathologies and in traumatic lesions. 
For example, 2,4-disulfophenyl-N-tert-butylnitrone (NXY-059) has neuroprotective 
effects when applied 4–5 hr post-occlusion at equimolar doses to PBN and reduced 
infarct volume from 37.2 to 12.5% when 30 mg/kg was administered i.v. 1 h after 
reperfusion in Wistar rats [121–124]. Meanwhile, stilbazulenyl nitrone (STAZN) 
exerts similar effects at lower doses than the one used for NXY-059; in fact, the toler-
ability and safety of NXY-059 were studied in patients with acute stroke in clinical 
trials [103, 124]. Although not all compounds have demonstrated their neuroprotec-
tive effect when administered 24 h after the traumatic event, some of them have 
allowed favoring the therapeutic window at repeated doses [103].
Other derivatives are 5,5-dimethyl-1-pyrroline-N-oxide (DMPO) and diesteri-
fied nitrone (EMEPO), which have shown similarities to the action of PBN but 
with some other advantages, such as being less toxic and increasing the levels of 
antiapoptotic proteins such as Bcl2 and p-Bad and decreasing the synthesis of 
pro-apoptotic ones such as caspase 3, p53, and Bax [125–127]. In addition, (2, 2, 6, 
6-tetramethylpiperidin-1-yl)oxyl (Tempo) and (4-hydroxy-2,2,6,6-tetramethylpi-
peridin-1-yl)oxyl (Tempol) have shown antioxidant properties in radiation damage 
and injury [128, 129]. In a traumatic brain injury mouse model, Tempol reduced 
post-traumatic LP and oxidative damage induced by protein nitration, decreasing 
mitochondrial damage, cytoskeletal damage, and neurodegeneration and improv-
ing motor function [128, 130, 131].
Despite the results observed with the nitrones and the wide range of studies per-
formed for therapeutic uses at different doses and times, their action is attributed 
to their ability to form adducts, but not before indicating the possible participation 
of other mechanisms that favor their neuroprotective activity, thus expanding the 
information on antioxidant therapy strategies in the clinical area.
3.10 Polyethylene glycol (PEG)-superoxide dismutase (SOD)
Polyethylene glycol (PEG) is a surfactant that due to its hydrophilic nature 
allows the fusion and fluidity of the cell membrane that reduces the oxidative 
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effects of the secondary stage and that during the acute phase of SCI, it may 
inhibit nerve fiber degeneration and create a favorable microenvironment for the 
regeneration of nerve filaments that can stimulate angiogenesis and reduce glial 
scar, promoting the regeneration of axonal guidance and motor recovery. PEG has 
been widely used as a scaffold for a large variety of molecules in treatment for SCI 
[132–136], while the SOD enzyme has antioxidant properties, as mentioned previ-
ously. The combination of SOD with PEG (PEG-SOD) allows an increase of the 
enzyme intracellularly and its antioxidant activity, and it may have an important 
role in vascular relaxation by reducing the concentration of O2•− and limiting the LP 
[132]. It has been used in myocardial ischemia and in lung injury models, proposed 
as a treatment vs. oxidative stress [132].
In a controlled phase II study in patients in a coma who suffered a stroke and 
received a single i.v. dose of 2000, 5000, or 10,000 IU/kg 4 h after the injury, its 
recovery was better in comparison to the group that received placebo (44% were 
in a vegetative state or died); no side effects were observed in this study due to the 
administration of the drug [137].
In a study in a cerebral ischemia model performed in rats, 10,000 IU/kg of PSG-
SOD were i.v. administered, and the group presented a significant reduction in infarct 
size in comparison to the control group [138]. In other study with Sprague-Dawley 
male rats (300-350g of weight), an occlusion of the hepatic artery was performed and 
reperfusion was performed after 90 min to generate liver damage. A group of animals 
received i.v. 5000 U/kg of PEG-SOD before vascular occlusion and immediately after 
reperfusion, while the control group only received a saline solution following the same 
scheme. In the group treated with PEG-SOD, hepatic ischemia and LP were attenuated. 
Meanwhile, another study examined the effect of PEG-SOD on focal cerebral ischemia/
reperfusion in rats; the results showed that the effect is variable, depending on the 
dosage [132, 139]. In a dog experiment, thoracic aortic cross-clamping was performed; 
a dose of 5000 U/kg of PEG-SOD was i.v. administered to one group 15–20 min before 
clamping, and the other group only received a saline solution. Delayed paraplegia was 
avoided in the group of dogs that received the conjugate, unlike the groups that did not 
receive it [140]. Edward et al. conducted an important review of the use of PEG-SOD in 
phase II and III studies in traumatic brain injury [141].
3.11 Mannitol
When mannitol is used for medical purposes, it is administered intravenously. 
Mannitol can be found in varying concentrations, dissolved in 100 mL of fluid (5, 20, 
and 25% mannitol). A common solution is 20% mannitol. Cruz and colleagues described 
the dose-response effect of preoperative mannitol on acute subdural hematomas in 
traumatic brain injury in which mannitol therapy has been classically directed, establish-
ing and maintaining an osmotic gradient between the blood and brain [142, 143].
Maintaining an adequate spinal cord perfusion pressure is crucial after 
SCI. Intramedullary edema within the spinal cord and consecutively raised intra-
thecal pressure at the injury are important secondary injury mechanisms in the 
pathobiology after traumatic SCI. Increased intraspinal pressure reduces spinal cord 
perfusion pressure, which leads to worsen post-traumatic ischemia [144].
Mannitol allows the control of blood flow patterns in the spinal cord; it has been 
used experimentally in some studies in rats that have suffered a controlled SCI and 
in dogs/cats that suffer an SCI within the clinical area. Mannitol is recommended to 
reduce the effect of inflammation and edema, an effect that has been corroborated 
with microangiographic and electrophysiological studies. One hour after the appli-
cation of a 3 g/kg dose, an improved intramedullary vascular pattern was detected 
among the animals treated with mannitol compared to those that were not treated, 
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and 4 h after the perfusion, many areas of the lateral white matter of the spinal cord 
were almost normal [145]. In a study in dogs, an SCI was experimentally induced, 
and it was reported that mannitol alone did not help to reverse the paralysis of these 
animals [146]; however, another study stated that the i.v. administration of man-
nitol at a dose of 2 g/kg had a good effect on the white matter of the spinal cord and 
areas of the brain [147]. In a retrospective study with Sprague-Dawley rats, a group 
with SCI by compression by means of a clamp, 2 g/kg mannitol were administered 
immediately after the injury, while the control group was given 0.9% saline solu-
tion; all groups underwent structural and electrophysiological studies. The group 
treated with mannitol obtained excellent results, finding significant improvement 
in neural structures and protection of the spinal cord after SCI [148]. In a study in 
dogs to which an edema was induced by severe external spinal cord trauma, 3 g/kg 
of mannitol was i.v. administered, and they were neurologically evaluated, and a 
myelography study was performed after 2 h of the treatment, to identify the edema, 
showing that there was reduction of it [149].
3.12 Combinatory therapies and results in symptoms of SCI
In addition to its independent use, several studies have evaluated the use of 
one or more antioxidants together by themselves or in addition to other existing 
therapies for SCI, such as rehabilitation exercise or cell transplantation, expect-
ing a synergism to enhance the recovery. Moreover, some therapies not only aim 
to improve the immediate treatment of SCI but also improve the effects it has on 
relieving the most common complications in patients. To mention some, the com-
bination of vitamin C as antioxidant (100 mg/kg/1 h and daily/28d, i.p.) together 
with the transplantation of bone marrow mesenchymal stem cells (BMMSC) (3 × 
106 cells) induced improvements in motor recovery in rats when compared with 
methylprednisolone (MP), vitamin C, or BMMSC alone in SCI [150]; simultaneous 
administration of vitamin D (5 μg/kg/twice daily) and progesterone (0.5 mg/kg/
twice daily i.m.) for 5 days demonstrated a higher efficacy in reducing neuroin-
flammation in comparison to when they were administered separately, and when 
they were administrated early (first 4 h) in SCI patients receiving MP, there was 
improvement in the motor and sensory functions 6 months after starting therapy 
[151]. Applying once a day a combination of low-dose fluoxetine (1 mg/kg/i.p.) 
and vitamin C (100 mg/kg/i.p.) immediately after the event and for 14 days had a 
protective effect on the BSCB integrity, improving the functional recovery, showing 
inhibition of the expression and activation of the matrix metalloproteinase, and 
decreasing the infiltration of leukocytes and the expression of inflammatory and 
oxidizing molecules, but not when they were applied separately in rats [152]. In 
SCI patients, dietary supplementation for 3 months, which included three 750 mg 
per day of omega-3 fatty acids and antioxidants (400 mg of mixed tocopherols, 
coenzyme Q10, curcumin, etc.), caused a decrease of inflammatory cytokines with 
reduction in neuropathic pain [153]; 2 months vitamin E dietary supplementation 
765–1020 IU/day in rats before SCI showed accelerated bladder recovery, significant 
motor improvement, and a high number of oligodendrocytes compared to the 
controls [154].
4. Conclusion
After a primary injury occurs on the spinal cord, destructive biochemical 
mechanisms are initiated (secondary injury) that play a fundamental role in the 
pathophysiology of spinal cord injury. Within these, oxidative stress and lipid 
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peroxidation exacerbate the biochemical mechanisms once initiated and propagate 
neurodegenerative damage, so the degree of loss of long-term motor and sensory 
functions depends largely on their intensity. This damage suffered during the acute 
phase and that may be irreversible requires a timely intervention. To guarantee 
the antioxidant effect that will render better results, it is important to consider the 
new agents and therapies in the SCI treatment at the appropriate times. There is no 
fully restorative therapy for SCI, but strategies for the modulation of this damage 
contribute to neuroprotection and, although partially, to functional recovery.
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Acronyms and abbreviations
aa amino acids
ADH alcohol dehydrogenase
ALDH aldehyde dehydrogenase
BSCB blood-spinal cord barrier
BMMSC bone marrow mesenchymal stem cells
CAT catalase
CD cluster of differentiation
CNS central nervous system
CO3
⦁− carbonate radical
COX cyclooxygenase
DHA docosahexaenoic acid
DNP dinitrophenyl
EPA eicosapentaenoic acid
ER estrogen receptor
FR free radicals
GAP-43 growth-associated protein 43
GFAP glial fibrillary acidic protein
GPx glutathione peroxidases
GR glutathione reductases
GSH glutathione, reduced
GSH-MEE glutathione monoethyl ester
GSSG glutathione, oxidized
GST glutathione S-transferases
HNE 4-hydroxy-2-nonenal
H2O2 hydrogen peroxide
HO⦁ hydroxyl radical
HO− hydroxyl anion
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IFN-γ interferon gamma
IL interleukin
iNOS inducible nitric synthase
L⦁ lipid radical
LH lipid
LP lipid peroxidation
LOO⦁ lipid peroxyl radical
LO⦁ lipid alkoxyl radical
LOOH lipid hydroperoxide
MLIF monocyte locomotion inhibitory factor
MDA malondialdehyde
MP or MPSS methylprednisolone sodium succinate
NAC N-acetyl cysteine
NADPH nicotinamide-adenine dinucleotide phosphate, reduced
NO⦁ nitric oxide
NO2
•− nitrogen dioxide radical
NOS nitric oxide synthase
NT-3 3-nitrotyrosine
O2
⦁− superoxide
OONO− peroxynitrite
PBN phenyl N-tert-butylnitrone
PEG polyethylene glycol
PEG-SOD polyethylene glycol-superoxide dismutase
PUFA polyunsaturated fatty acid
ROS reactive oxygen species
RNS reactive nitrogen species
RO2
⦁/HO2
⦁ peroxyl radical
SCI spinal cord injury
SOD superoxide dismutase
TGF-β transforming growth factor beta
TNF-α tumor necrosis factor alpha
VCAM-1 vascular cell adhesion molecule-1
VDH vitamin D: 1,25-dihydroxyvitamin D3
VLA-4 very late antigen 4
XO xanthine oxidase
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